PlumX Metrics
Embed PlumX Metrics

Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology, ISSN: 0344-5704, Vol: 34, Issue: 5, Page: 444-446
1994
  • 4
    Citations
  • 0
    Usage
  • 2
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

A total of 43 patients with advanced, previously untreated non-small-cell lung cancer (NSCLC) were treated with a novel nitrosourea, fotemustine, given at 100 mg/m on days 1 and 8. Maintenance treatment consisted of a single injection of 100 mg/m given every 21 days. 37 patients were evaluable for respone. Of these, 5 patients had a partial response (13.5%; 95% confidence interval, 6%-28%). Toxicity comprised mainly anaemia and thrombocytopenia. Other toxicities were mild. This phase II study confirms that fotemustine is a moderately active and well-tolerated drug in NSCLC. © 1994 Springer-Verlag.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know